v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities:    
Net loss $ (7,817,202) $ (5,653,573)
Depreciation and amortization 3,356,752 2,985,850
Interest from amortization of loan issuance costs 161,905 0
Loss on extinguishment of debt 418,502 0
Change in fair value of warrant Liability (870,554) 0
Loss on disposal of property and equipment 80,505 13,248
Stock-based compensation on stock options, RSUs & RSAs, net 745,155 763,258
Provision for credit losses (3,014) (4,422)
Change in operating lease assets and liabilities (91,582) 47,693
Inventory write-offs to allowance 135,625 95,539
Deferred taxes (2,368) 8,573
Changes in operating assets and liabilities, net of acquisitions:    
Trade accounts receivable (822,043) 1,766,594
Other current assets 73,362 (419,797)
Inventories (1,206,340) 725,460
Prepaid expenses and deposits (360,439) 95,900
Accounts payable and accrued liabilities 520,289 32,020
Net cash (used in) provided by operating activities (5,681,447) 456,343
Cash flows from investing activities:    
Purchase of property and equipment (580,726) (1,892,660)
Proceeds from sale of equipment 10,648 0
Proceeds from sale-leaseback of equipment 0 364,710
Acquisition of G5 (20,250,011) 0
Acquisition of Visimid, net of cash acquired 0 (847,141)
Net cash used in investing activities (20,820,089) (2,375,091)
Cash flows from financing activities:    
Proceeds from exercise of stock options 3,175 0
Proceeds from sale of common stock from Employee Stock Purchase Plan 14,385 39,677
Proceeds from issuance of common stock under public equity placement, net of fees 0 98,208
Proceeds from issuance of common stock under private equity placement, net of fees 437,725 0
Proceeds from issuance of preferred stock under private equity placement, net of fees 18,842,138 0
Proceeds from issuance of warrants under private equity placement 4,620,561 0
Deferred payment for acquisition of Visimid (125,000) 0
Borrowings on loans payable 6,659,596 142,853
Loan issuance costs (597,465) 0
Payments on loans payable (149,118) (2,262,798)
Repayment of finance lease obligations (133,711) (87,610)
Net cash provided by (used in) financing activities 29,572,286 (2,069,670)
Effect of exchange rate on cash and cash equivalents (72,133) 2,880
Change in cash, cash equivalents and restricted cash 2,998,617 (3,985,538)
Cash, cash equivalents and restricted cash, beginning of period 3,480,268 7,144,490
Cash, cash equivalents and restricted cash, end of period 6,478,885 3,158,952
Supplemental disclosure of cash flow information:    
Interest paid in cash 66,136 161,676
Income taxes paid 118,016 120,787
Supplemental disclosure of non-cash investing & financing activities:    
Purchase of equipment through finance lease arrangements 93,048 391,107
Issuance of common stock for acquisition of Visimid 713,946 486,054
Issuance of common stock for acquisition of G5 4,872,068 0
Accrual of earnout consideration for acquisition of G5 2,501,000 0
Extinguishment of debt in exchange for common stock, preferred stock warrants and a note $ 3,057,110 $ 0